We do not redo that work.
What we do is look at the drug within the context of other drugs we currently fund for the same purpose within British Columbia—how it fits within that therapeutic group. We'll take a look at what the budget impact of implementation will be for the province and make a determination as to whether we feel it is affordable for British Columbia and whether there are any other overriding policies that we have adopted, within pharmaceutical services or within the province, that would have an impact on our being able to implement the recommendation of CADTH. But we do not redo the evidential, critical appraisal process.